fluoxastrobin: a fungicide
fluoxastrobin : An oxime O-ether that is the O-methyl oxime of (2-{[6-(2-chlorophenoxy)-5-fluoropyrimidin-4-yl]oxy}phenyl)(5,6-dihydro-1,4,2-dioxazin-3-yl)methanone. A fungicide used for disease control of potatoes and a wide range of vegetables.
ID Source | ID |
---|---|
PubMed CID | 11048796 |
CHEMBL ID | 1902591 |
CHEBI ID | 83253 |
SCHEMBL ID | 350134 |
SCHEMBL ID | 18719 |
MeSH ID | M0547224 |
Synonym |
---|
(1e)-(2-((6-(2-chlorophenoxy)-5-fluoro-4-pyrimidinyl)oxy)phenyl)(5,6-dihydro-1,4,2-dioxazin-3-yl)methanone o-methyloxime |
fluoxastrobin [iso] |
hec 480 sc |
(e)-(2-{[6-(2-chlorophenoxy)-5-fluoropyrimidin-4-yl]oxy}phenyl)(5,6-dihydro-1,4,2-dioxazin-3-yl)methanone o-methyloxime |
361377-29-9 |
fluoxastrobin |
NCGC00168310-01 |
NCGC00168310-02 |
193740-76-0 |
fluoxastrobin (e,z isomer) |
dtxcid0014625 |
NCGC00254728-01 |
tox21_300824 |
dtxsid2034625 , |
cas-361377-29-9 |
hsdb 7880 |
disarm |
xq43wy091y , |
unii-xq43wy091y |
AKOS015909404 |
hec-480sc |
fluoxastrobin [mi] |
(e)-(2-(6-(2-chlorophenoxy)-5-fluoropyrimidin-4-yloxy)phenyl)(5,6-dihydro-1,4,2-dioxazin-3-yl)methanone o-methyloxime |
SCHEMBL350134 |
SCHEMBL18719 |
(e)-1-(2-{[6-(2-chlorophenoxy)-5-fluoropyrimidin-4-yl]oxy}phenyl)-1-(5,6-dihydro-1,4,2-dioxazin-3-yl)-n-methoxymethanimine |
CHEBI:83253 , |
CHEMBL1902591 |
fluoxastrobin, pestanal(r), analytical standard |
(2-((6-(2-chlorophenoxy)-5-fluoropyrimidin-4-yl)oxy)phenyl)(5,6-dihydro-1,4,2-dioxazin-3-yl)methanone o-methyl oxime |
E76505 |
fluxastrobin |
(e)-1-[2-[6-(2-chlorophenoxy)-5-fluoropyrimidin-4-yl]oxyphenyl]-1-(5,6-dihydro-1,4,2-dioxazin-3-yl)-n-methoxymethanimine |
Q27269858 |
(z)-fluoxastrobin |
Role | Description |
---|---|
mitochondrial cytochrome-bc1 complex inhibitor | null |
antifungal agrochemical | Any substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
oxime O-ether | O-organyl oximes R2C=NOR' (R' =/= H). |
aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
pyrimidines | Any compound having a pyrimidine as part of its structure. |
dioxazine | Any six-membered organic heteromonocyclic compound that contains one nitrogen and two oxygen atoms. |
organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
monochlorobenzenes | Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine. |
strobilurin antifungal agent | Any antibiotic antifungal agents whose structure is based on the antifungal agents originally isolated from the fungus Strobilurus tenacellus. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 0.7079 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 1.1943 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
SMAD family member 2 | Homo sapiens (human) | Potency | 30.8805 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
SMAD family member 3 | Homo sapiens (human) | Potency | 30.8805 | 0.1737 | 34.3047 | 61.8120 | AID1346924 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 1.0723 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 6.9130 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588515; AID588516; AID743035; AID743042; AID743053; AID743054; AID743063 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 19.3115 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 23.1254 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 27.2783 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 5.5983 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 36.4321 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531; AID588546 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 3.5157 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 45.1977 | 0.3758 | 27.4851 | 61.6524 | AID588526; AID743217 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 27.2783 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 16.0531 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID588513; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 45.1977 | 0.0010 | 24.5048 | 61.6448 | AID588534; AID743215 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 28.8109 | 0.0010 | 19.4141 | 70.9645 | AID588536; AID588537; AID743094; AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 40.7836 | 0.0237 | 23.2282 | 63.5986 | AID588541; AID743222 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 54.4273 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 12.8093 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 48.9423 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 29.9033 | 0.0100 | 39.5371 | 1,122.0200 | AID588545; AID588547 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 0.7610 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 54.9141 | 0.0420 | 27.3789 | 61.6448 | AID743210 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 0.6282 | 0.0006 | 27.2152 | 1,122.0200 | AID743202; AID743219 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 4.8508 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 41.3055 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID651743 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 4.8508 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (11.11) | 29.6817 |
2010's | 4 (44.44) | 24.3611 |
2020's | 4 (44.44) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (30.66) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |